Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat …MarketWatch (press release)The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controll…
Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent …Sacramento BeeThe poster discussion session will highlight data from the ibrutinib Phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory …
Clinical Oncology NewsCHOP-RIT, CHOP-R Similar for Follicular LymphomasClinical Oncology NewsSan Diego—Radiolabeled iodine-131 tositumomab (RIT) and rituximab have similar efficacy and tolerability when either is combined with CHOP (cyclophosphamide,…
Daiichi Sankyo teams up with US firm to develop biosimilarsMainichi Daily NewsDaiichi Sankyo will introduce relevant technology from Coherus BioSciences to develop biosimilar forms of etanercept for rheumatism treatment and rituximab for cancer treatme…
OncLiveMeeting the Challenges in Treating Lymphoma A Conversation With Andrew D …OncLiveDr Zelenetz: The standard of care for diffuse large B-cell lymphoma (DLBCL) in the United States remains rituximab (R) in combination with cyclophosphamide, doxor…
Compulsory licensing sets off a wave of price cuts in cancer drugsLivemintSome of the key cancer drugs under patent protection in India—erlotinib (lung cancer), sunitinib (kidney cancer), sorafenib (liver and kidney cancer), trastuzumab (breast cance…
Rituximab Promotes Long-Term Response for Patients with Immune Destruction of …Business Review India (press release)WASHINGTON, May 7, 2012 /PRNewswire-USNewswire/ — A new analysis concludes that rituximab, a drug commonly used to treat blood cancer…
Rituximab promotes long-term response for patients with immune destruction of …Medical XpressA new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximate…
Rituximab Promotes Long-Term Response for Patients with Immune Destruction of …MarketWatch (press release)WASHINGTON, May 7, 2012 /PRNewswire via COMTEX/ — A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads t…
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To …MarketWatch (press release)Ltd. (hereafter, Daiichi Sankyo; TSE 4568) announced today the execution of an exclusive agreement to develop and commercialize biosimilar forms o…